PFE vs RTX: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and RTX Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
RTX Corporation · Industrials
$185.60
-25.2% upside to fair value
Grade D
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
RTX |
| Current Price |
$25.22 |
$185.60 |
| Fair Value Estimate |
$25.92 |
$138.81 |
| Upside to Fair Value |
+2.8%
|
-25.2%
|
| Market Cap |
$143.7B |
$249.9B |
| Forward P/E |
19.2x
|
34.3x
|
| EV / EBITDA |
12.3x
|
18.3x
|
| Price / Sales |
2.3x
|
2.8x
|
| Price / FCF |
15.2x
|
29.9x
|
| Revenue Growth YoY |
+5.4%
|
+8.7%
|
| Gross Margin |
69.3%
|
20.2%
|
| Operating Margin |
23.4%
|
10.9%
|
| Return on Equity |
8.4%
|
11.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.6%
|
3.34%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
RTX Corporation is a leading aerospace and defense company with a strong competitive moat driven by scale and an installed base in commercial aerospace via Pratt & Whitney and Collins Aerospace, and defense through Raytheon. The company benefits from a large multi-year backlog of approximately $270 billion supporting steady cash flow and mid-single-digit organic growth. Despite solid revenue grow…
Accumulation Zones
| Metric |
PFE |
RTX |
| Zone Low |
$19.44 |
$104.11 |
| Zone High |
$22.03 |
$117.99 |
| In Buy Zone? |
No
|
No
|